U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07616128) titled 'Study of EVO756 in Adults With Migraine' on May 19.
Brief Summary: This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Migraine
Intervention:
DRUG: EVO756, Dose 1
Orally administered EVO756, Dose 1 (Daily)
DRUG: EVO756, Dose 2
Orally administered EVO756, Dose 2 (Daily)
DRUG: Placebo
Placebo Control (Daily)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Evommune, Inc.
Disclaimer: Curated by HT Syndication....